Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,579
  • Shares Outstanding, K 18,566
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,070 K
  • 60-Month Beta 1.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.86
Trade ENLV with:

Options Overview Details

View History
  • Implied Volatility 200.45% ( -154.60%)
  • Historical Volatility 247.21%
  • IV Percentile 61%
  • IV Rank 25.24%
  • IV High 758.36% on 09/26/23
  • IV Low 12.13% on 01/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 352
  • Volume Avg (30-Day) 414
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 2,586
  • Open Int (30-Day) 4,715

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +35.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +16.52%
on 04/15/24
4.5900 -70.81%
on 04/03/24
-2.3400 (-63.59%)
since 03/22/24
3-Month
1.1500 +16.52%
on 04/15/24
4.5900 -70.81%
on 04/03/24
-1.4500 (-51.97%)
since 01/23/24
52-Week
1.1500 +16.52%
on 04/15/24
4.5900 -70.81%
on 04/03/24
-1.6200 (-54.73%)
since 04/21/23

Most Recent Stories

More News
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 1.3300 (+4.72%)
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic...

ENLV : 1.3300 (+4.72%)
Enlivex to Present at the 2022 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy...

ENLV : 1.3300 (+4.72%)
Enlivex Announces Upcoming May Conference Presentations

Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 1.3300 (+4.72%)
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy. Immune checkpoint inhibitors targeting...

ENLV : 1.3300 (+4.72%)
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 1.3300 (+4.72%)
Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates

Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex’s R&D efforts during the last two years, was successfully completed in...

ENLV : 1.3300 (+4.72%)
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.

NVS : 97.31 (+2.30%)
MESO : 5.98 (+8.14%)
BCDA : 0.3698 (+0.54%)
ENLV : 1.3300 (+4.72%)
Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine

Publication follows the Israeli Ministry of Health’s appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19...

ENLV : 1.3300 (+4.72%)
Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...

ENLV : 1.3300 (+4.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 1.3600
2nd Resistance Point 1.3300
1st Resistance Point 1.3000
Last Price 1.3300
1st Support Level 1.2400
2nd Support Level 1.2100
3rd Support Level 1.1800

See More

52-Week High 4.5900
Fibonacci 61.8% 3.2759
Fibonacci 50% 2.8700
Fibonacci 38.2% 2.4641
Last Price 1.3300
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar